Next 10 |
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) . Appili is a biopharmaceutical company focused on drug develo...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 63.6% to $0.168949 on volume of 119,634,330 shares C3is Inc. (CISS) rose 17.5% to $0.0424 on volume of 56,452,737 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 6.6% to $3.315 on volume...
2024-04-02 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
2024-04-02 08:51:10 ET More on Aditx Therapeutics, Appili Therapeutics, etc. Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M Aditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devices Financial information ...
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX),...
2024-04-01 08:31:15 ET More on Pre-market losers & stocks. MicroStrategy Is A $1 Box Of Bitcoin Trading For $1.91 Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript MicroStrategy: A Bad Deal For Investors MicroStrategy among most squeezable ...
Aditxt (NASDAQ: ADTX) previously entered into a definitive agreement to acquire Evofem Biosciences Inc. (OTCQB: EVFM) , which is believed to represent a compelling opportunity to accelerate Evofem’s growth trajectory, as a subsidiary of Aditxt, into a multi-product women’s health ...
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 PR Newswire -- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percent...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
News, Short Squeeze, Breakout and More Instantly...
ADiTx Therapeutics Inc. Company Name:
ADTX Stock Symbol:
NASDAQ Market:
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods post...
Aditxt, Inc. (NASDAQ:ADTX) shares are volatile Tuesday after the company announced it will acquire Appili Therapeutics. The Details: Aditxt’s...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and...